Title |
Treatment implications of posterior fossa ependymoma subgroups
|
---|---|
Published in |
Cancer Communications, November 2016
|
DOI | 10.1186/s40880-016-0155-6 |
Pubmed ID | |
Authors |
Vijay Ramaswamy, Michael D. Taylor |
Abstract |
Posterior fossa ependymoma comprises two distinct molecular entities, ependymoma_posterior fossa A (EPN_PFA) and ependymoma_posterior fossa B (EPN_PFB), with differentiable gene expression profiles. As yet, the response of the two entities to treatment is unclear. To determine the relationship between the two molecular subgroups of posterior fossa ependymoma and treatment, we studied a cohort of 820 patients with molecularly profiled, clinically annotated posterior fossa ependymomas. We found that the strongest predictor of poor outcome in patients with posterior fossa ependymoma across the entire age spectrum was molecular subgroup EPN_PFA, which was recently reported in the paper entitled "Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis" in the Journal of Clinical Oncology. Patients with incompletely resected EPN_PFA tumors had a very poor outcome despite receiving adjuvant radiation therapy, whereas a substantial proportion of patients with EPN_PFB tumors can be cured with surgery alone. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 52 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 9 | 17% |
Other | 6 | 12% |
Student > Bachelor | 6 | 12% |
Student > Doctoral Student | 5 | 10% |
Student > Ph. D. Student | 5 | 10% |
Other | 10 | 19% |
Unknown | 11 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 33% |
Biochemistry, Genetics and Molecular Biology | 16 | 31% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Agricultural and Biological Sciences | 2 | 4% |
Neuroscience | 2 | 4% |
Other | 2 | 4% |
Unknown | 11 | 21% |